Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue.
In an interview with MedCity News on day three of the BIO International Convention, Ricks discussed his company's newly expanded R&D facility in San Diego, the challenges of drug discovery, and the ultimate reward.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Eli Lilly has publicized plans to invest $850 million in the United States throughout 2017, expanding operations in Indiana and doubling-down on diabetes manufacturing. Just what the president wants to hear.